Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)
Last Updated: Thursday, July 10, 2025
An evaluation of the presentation and management of cranial neuropathy in patients treated with ciltacabtagene autoleucel (cilta-cel) across the CARTITUDE-1, -2, and -4 trials. Out of 332 patients receiving cilta-cel across the trials, 21 patients (6.3%) developed cranial neuropathy. Most cases were low grade and were resolved with corticosteroids.
Advertisement
News & Literature Highlights